Danish medical journal · 2026
Acute haemodynamic and diuretic effects of intravenous furosemide in acute heart failure.
Клиническое исследование I фазыКлиническое исследование II фазыСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Caidi Nora Olsen, Lukoschewitz Jasmin Dam, Taraldsen Ida Arentz, Hove Jens, Seven Ekim, Dixen Ulrik, Grund Frederik, Petersen Morten, Foss Nicolai Bang, Grand Johannes
Аннотация
INTRODUCTION: While the diuretic effect of loop diuretics in acute heart failure (AHF) is well established, it remains debated whether furosemide exerts any extrarenal decongestive effects. This study aimed to examine the acute effects of furosemide on pulmonary congestion, diuresis and haemodynamics in patients hospitalised with AHF.
METHODS: We conducted a prospective interventional study including 20 AHF patients, each receiving 80 mg of intravenous furosemide at baseline. Diuresis, perfusion index, echocardiography and pulmonary fluid via remote dielectric sensing (ReDS) were assessed at predefined time points until 360 minutes. The primary endpoint was a change in ReDS within 30 minutes.
RESULTS: The cohort had a mean age of 78 ± 9 years, with 65% diagnosed with heart failure with reduced ejection fraction. Baseline ReDS was 35.3 ± 1.8%. No significant reduction in ReDS was observed at any time point; a non-significant decrease of 1.7% was observed at 20 minutes (p = 0.32). Diuresis reached 134 ± 56 ml by 20 minutes (p = 0.02). Perfusion index declined significantly by 25 minutes (p = 0.03) and remained stable until 120 minutes. No other haemodynamic parameters changed significantly.
CONCLUSIONS: Intravenous furosemide did not acutely reduce pulmonary fluid before diuresis, suggesting no immediate extrarenal effect. Haemodynamic changes occurred only after diuresis, indicating its primary acute action is diuretic, with later responses likely being secondary to volume loss.
FUNDING: None.
TRIAL REGISTRATION: The protocol was registered with clinicaltrials.gov on 29 August 2023 (Identifier: NCT06024889).
METHODS: We conducted a prospective interventional study including 20 AHF patients, each receiving 80 mg of intravenous furosemide at baseline. Diuresis, perfusion index, echocardiography and pulmonary fluid via remote dielectric sensing (ReDS) were assessed at predefined time points until 360 minutes. The primary endpoint was a change in ReDS within 30 minutes.
RESULTS: The cohort had a mean age of 78 ± 9 years, with 65% diagnosed with heart failure with reduced ejection fraction. Baseline ReDS was 35.3 ± 1.8%. No significant reduction in ReDS was observed at any time point; a non-significant decrease of 1.7% was observed at 20 minutes (p = 0.32). Diuresis reached 134 ± 56 ml by 20 minutes (p = 0.02). Perfusion index declined significantly by 25 minutes (p = 0.03) and remained stable until 120 minutes. No other haemodynamic parameters changed significantly.
CONCLUSIONS: Intravenous furosemide did not acutely reduce pulmonary fluid before diuresis, suggesting no immediate extrarenal effect. Haemodynamic changes occurred only after diuresis, indicating its primary acute action is diuretic, with later responses likely being secondary to volume loss.
FUNDING: None.
TRIAL REGISTRATION: The protocol was registered with clinicaltrials.gov on 29 August 2023 (Identifier: NCT06024889).